Humana
HUM
$400.00
+3.50%
Humana Inc. is one of the largest private health insurers in the United States, specializing in government-sponsored healthcare programs, with nearly all its medical membership derived from Medicare, Medicaid, and the military's Tricare program. The company has carved a distinct niche as a focused player in government-sponsored health plans, differentiating itself through integrated healthcare services including primary care, at-home services, and pharmacy benefit management under its CenterWell brand. The current investor narrative centers on Humana's strong recovery from a challenging 2025, driven by a favorable Medicare Advantage payment rate increase from CMS in April 2026 that boosted revenue visibility across the managed care sector. Attention is also focused on the company's ability to sustain margin improvement and membership growth amid regulatory changes and competitive pressures from larger diversified peers like UnitedHealth and CVS Health.…
HUM
Humana
$400.00
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Hold. Humana is a compelling recovery story, but the stock has already priced in much of the positive momentum, trading above the average analyst target of $346.71. The consensus recommendation is Buy, but the upside appears limited at current levels, warranting a cautious stance.
Supporting Evidence: Revenue grew 23.47% YoY in Q1 2026, and the company swung to a net income of $1.19B from a loss. Free cash flow turned positive at $1.13B. However, the trailing PE of 25.95x is above the 5-year average of ~18x, and the stock trades at a 17.95% premium to the industry average PE of 22.0x. The price-to-sales ratio of 0.24x is low, but this is typical for low-margin insurers. The implied downside to the average target is -13.3%, suggesting limited near-term upside.
Risks & Conditions: The biggest risks are valuation compression if earnings growth disappoints, regulatory changes to Medicare Advantage, and competitive pressure from larger peers. This Hold rating would upgrade to Buy if the stock pulls back to $350 or below (near the average target), or if forward guidance shows accelerating margin expansion. It would downgrade to Sell if revenue growth decelerates below 10% or if medical cost ratios spike. Overall, Humana appears fairly valued to slightly overvalued relative to its history and peers, given the current price above the consensus target.
Sign up to view all
HUM 12-Month Price Forecast
Humana's strong operational recovery and favorable regulatory tailwinds are offset by valuation concerns, as the stock has already priced in much of the good news. The base case of a range-bound stock near current levels is most likely, with a 50% probability. Upside to $502 is possible if margin expansion accelerates, but downside to $195 is equally plausible if regulatory or competitive pressures emerge. The neutral stance reflects the balanced risk/reward at current levels, with a slight tilt toward caution given the premium valuation. Upgrades would require a pullback to the average target or clearer evidence of sustained margin improvement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $346.71 and implied upside of -13.3% versus the current price.
Average Target
$346.71
0 analysts
Implied Upside
-13.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$195 - $502
Analyst target range
Humana is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.5 on a 1-5 scale where 1 is Strong Buy). The average target price is $346.71, which implies a downside of -13.3% from the current price of $400, indicating that the stock has already surpassed the consensus target. The distribution shows 10 analysts with Buy-equivalent ratings, 12 with Hold, and 2 with Sell, reflecting a cautiously bullish sentiment but with significant upside already realized. The target range spans from a low of $195.00 to a high of $502.00, representing a wide spread of $307.00. The high target of $502 implies 25.5% upside from the current price and likely assumes continued margin expansion, membership growth, and favorable regulatory outcomes. The low target of $195 suggests a 51.3% downside, pricing in risks such as adverse regulatory changes, competitive pressure, or a reversal in medical cost trends. Recent institutional ratings show a mix of Hold and Overweight ratings, with Wells Fargo upgrading from Equal Weight to Overweight on July 13, 2026, signaling increased optimism. The wide target spread indicates high uncertainty about Humana's future performance, driven by the binary nature of regulatory decisions and competitive dynamics in the Medicare Advantage market.
Drowning in data?
Find the real signal!
Bulls vs Bears: HUM Investment Factors
Humana presents a compelling recovery story with strong revenue growth, a return to profitability, and positive free cash flow, all supported by a favorable regulatory environment. However, the stock has already rallied 78.93% over the past year and now trades above the average analyst target, with a PE premium to its historical average. The bull case hinges on sustained margin improvement and membership growth, while the bear case centers on valuation risk and potential regulatory reversals. The single most important tension is whether the company can maintain its earnings recovery trajectory to justify the current valuation multiple, as any disappointment could trigger a sharp correction.
Bullish
- Strong Revenue Acceleration: Revenue grew 23.47% YoY in Q1 2026 to $39.65B, up from $32.11B in Q1 2025, driven by Medicare Advantage membership growth and favorable CMS payment updates.
- Sharp Profitability Recovery: Net income swung from -$796M in Q4 2025 to $1.19B in Q1 2026, with net margin improving from -2.45% to 2.99%, signaling a strong operational turnaround.
- Positive Free Cash Flow: Free cash flow turned positive at $1.13B in Q1 2026, reversing from -$1.85B in Q4 2025, with TTM FCF of $1.27B, providing financial flexibility.
- Favorable Regulatory Tailwind: CMS announced a larger-than-expected Medicare Advantage payment increase for 2027, boosting revenue visibility across the sector and directly benefiting Humana's core business.
Bearish
- Stock Trades Above Consensus Target: At $400, the stock is 15.4% above the average analyst target of $346.71, implying limited upside and potential overvaluation relative to analyst expectations.
- Elevated PE vs Historical Average: Trailing PE of 25.95x is above the 5-year average of ~18x, indicating the stock is priced for perfection and may be vulnerable to multiple compression if growth disappoints.
- Margin Compression Year-over-Year: Gross margin fell to 14.98% in Q1 2026 from 17.37% in Q1 2025, and net margin declined from 3.87% to 2.99%, showing profitability has not fully recovered.
- High Uncertainty in Analyst Targets: Analyst targets range from $195 to $502, a spread of $307, reflecting extreme uncertainty about future performance, particularly around regulatory and competitive dynamics.
HUM Technical Analysis
Humana is in a powerful sustained uptrend, with the stock surging 78.93% over the past year, dramatically outperforming the S&P 500's 18.35% gain. The current price of $400 sits at 93.3% of its 52-week range ($163.11–$428.88), indicating the stock is trading near the top of its range and reflecting strong bullish momentum. This positioning near highs suggests the market is pricing in continued positive catalysts, though it also raises the risk of short-term overextension. The 1-month price change of +10.50% and 3-month change of +94.99% show accelerating short-term momentum that far outpaces the 1-year trend, signaling a powerful breakout phase. The 3-month relative strength of +90.32% versus the S&P 500 confirms that Humana is leading the market decisively. However, the 1-month relative strength of +10.19% is lower than the 3-month figure, suggesting the pace of outperformance may be moderating slightly, which could indicate a potential consolidation or mean reversion in the near term. The 52-week low of $163.11 and high of $428.88 define the key support and resistance levels. A breakout above $428.88 would signal a continuation of the uptrend toward new highs, while a breakdown below $163.11 would be a severe bearish reversal. The stock's beta of 0.717 indicates it is less volatile than the overall market, which is unusual given its recent sharp moves; this low beta may reflect the defensive nature of the healthcare sector and the stock's strong correlation with regulatory developments rather than broad market swings.
Beta
0.72
0.72x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$429
Price range past year
Annual Return
+78.9%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +10.5% | -0.5% |
| 3m | +95.0% | +4.9% |
| 6m | +46.4% | +9.7% |
| 1y | +78.9% | +18.4% |
| ytd | +51.2% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Humana's revenue trajectory is accelerating, with Q1 2026 revenue of $39.65 billion growing 23.47% year-over-year, up from $32.11 billion in Q1 2025. The Insurance Segment generated $38.06 billion in revenue, while the CenterWell Segment contributed $6.10 billion, highlighting the dominance of the insurance business. Over the trailing four quarters, revenue has grown from $29.21 billion (Q4 2024) to $39.65 billion, reflecting a strong upward trend driven by Medicare Advantage membership growth and the favorable CMS payment update. The company swung to profitability in Q1 2026 with net income of $1.19 billion, compared to a net loss of $796 million in Q4 2025, demonstrating a sharp recovery. Gross margin improved to 14.98% in Q1 2026 from 11.67% in Q4 2025, though it remains below the 17.37% level seen in Q1 2025, indicating some margin compression year-over-year. The net margin of 2.99% in Q1 2026 is a significant improvement from the -2.45% in Q4 2025 but still below the 3.87% in Q1 2025, suggesting profitability is recovering but not yet at prior peaks. Humana's balance sheet shows manageable leverage with a debt-to-equity ratio of 0.73 and a current ratio of 0.72, indicating adequate liquidity. Free cash flow turned strongly positive at $1.13 billion in Q1 2026, reversing from -$1.85 billion in Q4 2025, and trailing twelve-month free cash flow stands at $1.27 billion. Return on equity (ROE) of 6.73% is modest but improving from negative levels in late 2025, and the company generated $1.25 billion in operating cash flow in Q1 2026, sufficient to cover capital expenditures of $121 million.
Quarterly Revenue
$39.6B
2026-03
Revenue YoY Growth
+23.5%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Since Humana's net income is positive (TTM net income of $1.19 billion in Q1 2026), the primary valuation metric is the price-to-earnings (PE) ratio. The trailing PE is 25.95x, while the forward PE is 24.95x, implying the market expects earnings growth over the next year. The slight discount in the forward multiple suggests modest growth expectations are already priced in. Humana's trailing PE of 25.95x is above the industry average PE of 22.0x (estimated from sector data), representing a 17.95% premium. This premium may be justified by Humana's focused exposure to the growing Medicare Advantage market and its recent earnings recovery, but it also reflects the market's optimism about regulatory tailwinds. The price-to-sales ratio of 0.24x is low relative to the industry average of 0.8x, indicating the stock is inexpensive on a sales basis, which is typical for low-margin health insurers. Compared to its own historical range, the current trailing PE of 25.95x is elevated relative to the 5-year average of approximately 18x (based on historical data from 2021-2025). The PE reached as low as 4.4x in Q1 2026 (due to depressed earnings) and as high as 40.1x in Q3 2025, so the current level is near the middle of the recent range. The price-to-book ratio of 1.75x is below the 5-year average of around 3.0x, suggesting the stock is trading at a discount to its historical book value multiple, which could indicate a value opportunity if earnings continue to recover.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Humana's debt-to-equity ratio of 0.73 is manageable, but the current ratio of 0.72 indicates potential liquidity pressure, as current liabilities exceed current assets. The company's net margin of 2.99% in Q1 2026, while improved, remains below the 3.87% in Q1 2025, showing that profitability recovery is incomplete. Additionally, the trailing PE of 25.95x is elevated relative to the 5-year average of ~18x, making the stock vulnerable to multiple compression if earnings growth slows. The reliance on Medicare Advantage for the majority of membership creates concentration risk, as any adverse regulatory change could significantly impact revenue and earnings.
Market & Competitive Risks: Humana trades at a premium to its historical PE, and the stock has already surpassed the average analyst target of $346.71, suggesting limited upside potential. Competitive pressure from larger diversified peers like UnitedHealth and CVS Health, which have broader product offerings and greater scale, could erode Humana's market share. The beta of 0.717 indicates lower market correlation, but the stock is highly sensitive to regulatory developments, as seen in the sharp moves following CMS announcements. Recent news highlights a favorable Medicare payment increase, but any future adverse changes could reverse sentiment quickly.
Worst-Case Scenario: If Medicare Advantage payment rates are cut, medical cost trends rise unexpectedly, or membership growth stalls, Humana could see earnings deteriorate. In such a scenario, the stock could fall to the analyst low target of $195, representing a 51.3% decline from the current price of $400. This would also approach the 52-week low of $163.11, implying a potential loss of 59.2% from current levels. The historical max drawdown of -47.54% suggests that severe corrections are possible, especially if the company's recovery narrative is disrupted.
FAQ
The key risks of holding Humana include: 1) Regulatory risk: Medicare Advantage payment rates are subject to annual CMS adjustments, and any adverse change could significantly impact revenue and earnings. 2) Valuation risk: The stock trades at a trailing PE of 25.95x, above its historical average, making it vulnerable to multiple compression if growth disappoints. 3) Competitive risk: Larger peers like UnitedHealth and CVS Health have greater scale and product breadth, which could pressure Humana's market share. 4) Liquidity risk: The current ratio of 0.72 indicates that current liabilities exceed current assets, which could strain finances if cash flow weakens. The most severe risk is a 51% decline to the analyst low target of $195.
The 12-month forecast for Humana is mixed, with a base case probability of 50% that the stock trades in a range of $347 to $400, near the average analyst target of $346.71. The bull case (25% probability) sees the stock reaching $450 to $502, driven by sustained margin expansion and favorable regulatory outcomes. The bear case (25% probability) sees a decline to $195 to $250, triggered by adverse regulatory changes or cost pressures. The most likely scenario is the base case, where the stock remains range-bound as the market digests the recent rally. Key assumptions include stable Medicare Advantage rates and continued membership growth.
Humana appears slightly overvalued relative to its historical valuation and analyst targets. The trailing PE of 25.95x is above the 5-year average of ~18x and the industry average of 22.0x, representing a 17.95% premium. The price-to-sales ratio of 0.24x is low compared to the industry average of 0.8x, but this is typical for low-margin health insurers. The stock also trades above the average analyst target of $346.71, implying a 13.3% downside. On a price-to-book basis, the ratio of 1.75x is below the 5-year average of ~3.0x, suggesting some value on a book value basis. Overall, the market is pricing in optimistic expectations for continued earnings recovery, leaving little room for error.
Humana is a good stock to buy for investors who believe in the Medicare Advantage growth story and are comfortable with the current valuation. The company has shown a strong recovery, with revenue growing 23.47% YoY and net income swinging to $1.19B in Q1 2026. However, the stock trades at a trailing PE of 25.95x, above its 5-year average of ~18x, and is 15.4% above the average analyst target of $346.71, suggesting limited near-term upside. The biggest downside risk is a 51% decline to the low target of $195 if regulatory or competitive pressures emerge. Therefore, it may be a better buy on pullbacks, especially if the price falls to $350 or below.
Humana is better suited for long-term investment given its focus on the growing Medicare Advantage market and its recent operational recovery. The stock's beta of 0.717 indicates lower volatility than the market, but its sensitivity to regulatory news can cause sharp short-term swings. The dividend yield of 1.39% provides modest income, but the payout ratio of 36.2% suggests room for growth. Short-term trading is risky due to the stock's recent 78.93% rally and its position above the average analyst target. A minimum holding period of 12-18 months is recommended to allow the recovery story to fully play out, with a focus on earnings growth and margin improvement.
